{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125921","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.178815+00:00","generated_at":"2026-05-30T00:57:58.080563+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ARS Pharma Q3 net loss $19.1M; neffy launch progressing; ALK deal $145M","bullets":["Net loss of $19.1M for Q3 2024; total revenue of $2.1M including $0.6M neffy product revenue from one week of sales.","Cash, equivalents & short-term investments $204.6M at Sept 30; pro forma $349.6M after $145M upfront from ALK-Abelló deal.","FDA granted priority review for neffy 1mg sNDA; PDUFA date March 6, 2025 for children weighing 15-30 kg.","Exclusive license with ALK-Abelló for neffy in Europe, Canada, etc.; total consideration up to $465M plus double-digit royalties.","Over 5,700 HCPs reached, 1,700+ prescriptions submitted, and 1,000 allergists enrolled in neffy Experience Program since launch."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125921","json":"https://secwatch.observer/filing/0000950170-24-125921.json","markdown":"https://secwatch.observer/filing/0000950170-24-125921.md","text":"https://secwatch.observer/filing/0000950170-24-125921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/0000950170-24-125921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024125921/spry-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:57:58.080563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}